Verily Health Awarded Centers for Disease Control and Prevention Contract to Support National Infectious Disease Wastewater Surveillance
Verily Health Awarded Centers for Disease Control and Prevention Contract to Support National Infectious Disease Wastewater Surveillance
Broader pathogen testing, genomic sequencing, and metagenomic capabilities under new agreement
Verily Health Inc., a healthcare data intelligence company, announced today that it has been awarded a contract by the Centers for Disease Control and Prevention (CDC) to continue supporting the national wastewater-based infectious disease surveillance program, building on the work that the company has performed for the CDC since 2023.
Under the new award, Verily Health will support CDC's National Wastewater Surveillance System through Verily Sightline, combining wastewater science, laboratory testing, data analytics, and technology to track infectious disease trends and support public health decision-making. The expanded program will continue pathogen testing, pathogen genomic sequencing, and include potential metagenomic capabilities, giving public health officials additional tools to monitor infectious diseases and respond to emerging threats.
"We're proud to continue our work with the CDC on a program that strengthens national public health surveillance," said Stephen Gillett, Chairman and CEO of Verily Health. "At Verily Health, we are building the data foundation for the future of healthcare intelligence, bringing together complex health data, scientific expertise, and advanced analytics to generate actionable insights that accelerate research and improve healthcare."
About Verily Health Inc.
At the intersection of technology, data science, and healthcare, Verily Health transforms complex health data into trusted intelligence, enabling health solutions that are more personal, predictive, and precise.
Verily’s flagship Governed Health Intelligence platform, Verily Pre, enables healthcare organizations to responsibly govern, model, and securely activate their protected health data at scale, deploying intelligence with the scientific rigor, oversight, and auditability needed for healthcare.
For more information about Verily Health, please visit verily.com.
Media Contact:
Laurie Ferguson
VP Communications
verily-press@verily.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261014116485/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States